

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number
34-13995-01

Docket or Reference number
030-02869

Amendment No. 16

Providence Hospital
Department of Nuclear Medicine
2446 Kipley Avenue
Cincinnati, OH 45239

In accordance with letter dated March 20, 1985, License Number 34-13995-01 is amended as follows:

Subitems 6.G., 7.G., and 8.G. are amended to read:

- | | | |
|---|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
| G. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35 | G. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35 | G. 2 curies total for all sources authorized in Subitem 6.G |

Condition 12. is amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

Vincent J. Seiwert, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

Henry J. Kenkel, M.D.

Groups I, II, III, IV and V
Xenon-133
In vitro studies

Thomas M. Morand, M.D.

Group VI
Phosphorus-ND32 as colloidal chromic phosphate for intracavitary treatment of malignant effusions

8506050484 850510
REQ3 LIC30
34-13995-01 PDR

For the U.S. Nuclear Regulatory Commission

Date May 10, 1985

Original Signed
By B. J. Holt
Materials Licensing Section, Region III

COPY

2
ml 30
38 5/10/85